Reducing immune-suppressing drugs after liver transplant
Part of Digestive system clinical trials.
This study tests a new way to lower the amount of immune-suppressing medicine needed after a liver transplant. It uses special treatments before or during the transplant to help your body accept the new liver with fewer drugs, which may reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having a liver transplant at Stanford University.
- You do not have conditions that make the study treatments unsafe, like pregnancy, severe immune problems, or previous radiation in the transplant area.
- You do not have liver cancer (except for certain skin cancers that have been treated) or any other active cancer.
- Your liver disease severity score (MELD) is 25 or less.
- You do not have hepatitis B, and if you have hepatitis C, it has been cured.
- You are not on dialysis and have not had another organ transplant before.
- You are not HIV positive, and your donor liver is from an HIV-negative person with ABO-compatible blood type and under 65 years old.
- You do not have an active infection at the time of transplant, and you are not pregnant or breastfeeding.
- You are willing to follow the study schedule, including extra biopsies, and can communicate with the research team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
This study tests if some liver transplant patients can safely take lower doses of their immune-suppressing medicines, potentially reducing side effects. It uses a biomarker test to guide the treatment changes.
Hear when a new Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.